Primatene Firm Expects Approval, Counts On Brand Equity, Target Market
This article was originally published in The Tan Sheet
Executive Summary
Amphastar Pharmaceuticals expects FDA to approve an amended NDA for Primatene HFA in 2016. Executives with the firm say sales of breath-triggered Primatene HFA could exceed annual revenues from the original Primatene Mist metered-dose inhaler before it was pulled from the market in 2011.
You may also be interested in...
Chronic Conditions Data Emphasize Need For Additional, Innovative OTCs
An NIH-funded study shows 92% of older consumers have chronic conditions, the primary target of FDA’s Nonprescription Safe Use Regulatory Expansion initiative to facilitate more Rx-to-OTC switches. The agency also extends the comment period for its initiative on making more ingredients available through the OTC monograph process.
Asthma Drug Petition Opposes OTC Approach, NSURE Paradigm
The developing Rx-to-nonprescription switch paradigm should exclude asthma and anaphylaxis drugs, advocates argue in a citizen petition. They say making inhalers available OTC contradicts the current standard for care.
Armstrong Juggles Reformulating Primatene Mist, Pushing To Sell Existing Inventory
Armstrong Pharmaceuticals plans to submit in the fourth quarter an NDA to FDA for an OTC asthma inhaler reformulated without chlorofluorocarbon as a propellant. The House Energy and Power Subcommittee proposes allowing the firm to sell its remaining inventory of CFC-containing Primatene Mist.